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Urothelial cell carcinoma (UCC) is the most common form of bladder cancer and is 
associated with the need for life-long surveillance once a patient is diagnosed with a non-
invasive disease. Due to the long-term risk of recurrence and the need for life-long routine 
monitoring and therapy, the cost per UCC patient from diagnosis to death is the highest of all 
cancers. The development of non-invasive biomarkers of recurrence and progression can 
increase survival, decrease treatment costs and improve patient quality of life. However, to 
date, no biomarker(s) have been endorsed for the use in the clinical management of UCC, 
especially in predicting risk of progression and recurrence. CTAG1B was previously found to 
be highly expressed in high-stage and grade bladder cancer, albeit in Caucasian cohorts. 
However, despite its potential as a target for cancer immunotherapy, the effect of expression 
modulation on cellular phenotypes has never been reported. In this study, we overexpressed 
CTAG1B in an invasive bladder cancer cell line, EJ28 after we confirmed that this cell line 
minimally expressed CTAG1B. The cells were transfected with CTAG1B-pcDNA3.1(-) and 
the level of expression was confirmed by qRT-PCR. Once the expression was confirmed to 
persist up to 72h post-transfection, the transfected cells were subjected to various phenotypic 
assays. In addition, the pattern of CTAG1B expression in a cohort of Malaysian bladder 
cancer paraffin-embedded tissues was also determined using immunohistochemistry. The 
effect of CTAG1B overexpression on the cell cycle, migratory and proliferative potential was 
observed. The changes in phenotype were compared with that of untransfected and mock 
controls. CTAG1B was overexpressed 20 times as compared to the untransfected and mock 
controls in the transfected cells. CTAG1B overexpression resulted in cells to migrate slower 
at 24h post-transfection but proliferate significantly faster after 72-96h post-transfection. In 
addition, CTAG1B was more frequently expressed in advanced bladder cancer stages and 
grades. The findings from this study contribute to the current knowledge of CTAG1B‟s role 
in tumourigenesis. Further functional studies will contribute towards realising the potential of 
CTAG1B as a biomarker for predicting the risk of progression and recurrence of bladder 
cancer. 24
